Year-end Sale % OFF 
Abstract
Multiple sclerosis (MS) is an immune-mediated, demyelinating disease of the central nervous system. In this study, an MS cohort and healthy controls were stratified into Caucasian and African American groups. Patient hematological profiles—composed of complete blood count (CBC) and complete metabolic panel (CMP) test values—were analyzed to identify differences between MS cases and controls and between patients with different MS subtypes. Additionally, random forest models were used to determine the aggregate utility of common hematological tests in determining MS disease status and subtype. The most significant and relevant results were increased bilirubin and creatinine in MS cases. The random forest models achieved some success in differentiating between MS cases and controls (AUC values: 0.725 and 0.710, respectively) but were not successful in differentiating between subtypes. However, larger samples that adjust for possible confounding variables, such as treatment status, may reveal the value of these tests in differentiating between MS subtypes.
Highlights
Multiple sclerosis (MS) is a complex disease of the central nervous system in which the myelin sheaths of the neurons in the brain and spinal cord are damaged
A minority of MS cases are classified as primary progressive multiple sclerosis (PPMS), in which disability accrues from disease onset without relapses
We performed three analyses: first, to better understand the physiological differences present in MS patients in general, we investigated whether differences exist in complete blood count (CBC) and complete metabolic panel (CMP) values between MS
Summary
Multiple sclerosis (MS) is a complex disease of the central nervous system in which the myelin sheaths of the neurons in the brain and spinal cord are damaged. As presentation of the disease varies widely between patients, several subtypes of MS have been defined based on patterns of its progression. Relapsing remitting multiple sclerosis (RRMS), the most common form of MS, is characterized by unpredictable attacks (with potentially permanent deficits) followed by periods of disease quiescence [1]. RRMS patients typically transition into secondary progressive multiple sclerosis (SPMS), which is characterized by steady disease progression. A minority of MS cases are classified as primary progressive multiple sclerosis (PPMS), in which disability accrues from disease onset without relapses. PPMS patients constitute only about 10% of all MS patients [2]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International journal of environmental research and public health
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
